Shenzhen Thistory Biomedical Co., Ltd. announced that it had completed Series B round of financing with more than 100 million yuan, led by Sherpavc Investment, and followed by CMAF Shenzhen.
Established in Shenzhen in 2017, Thistory Biomedical focuses on the diagnosis and prevention of cardiovascular and cerebrovascular diseases by aiming to create an innovation-driven, global-oriented, national medical device brand.
The YX series products for blood coagulation analysis, independently developed by Thistory Biomedical, for the first time innovated and merged the two major coagulation detection genres in the industry, making the company a pioneer in application innovation in the field of coagulation analysis; especially the YX-3000 products, whose performance in precision, speed, and reliability can all rival its top international counterparts.
According to Zhang Huali, General Manager of Thistory Biomedical, this round of financing has guaranteed the company sufficient cash flow, which will be used to carry out systematic construction for markets and channels.
Meanwhile, the company plans to launch more YX products to meet the needs of customers at different levels.
Zhang Huali said that with the funds, Thistory Biomedical would accelerate the development of its distributed assembly line analysis system, which could in turn raise the efficiency for product innovation significantly by adopting a brand-new analysis model architecture, and thereby, bring new innovation experience to its customers.